Karyopharm Therapeutics Inc
(STU:25K0)
€
6.15
-0.75 (-10.87%)
Market Cap: 141.01 Mil
Enterprise Value: 263.72 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 60/100 Karyopharm Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023 / 02:00PM GMT
Release Date Price:
€33.04
(-0.72%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I am happy to introduce our guests today, Richard Paulson, the President and CEO; and Reshma Rangwala, the CMO of Karyopharm Therapeutics. Thanks so much for joining us today.
Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director
Thanks for having us, Maury.
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
And we're going to do a fireside chat format. So maybe for those who are new to the story, if you can provide a 1-minute intro to Karyopharm.
Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director
Sure. I mean Karyopharm was founded in 2008 as an innovation and patient-focused company really driving a first-in-class focus on the selective inhibition of nuclear exports and developing an all-oral medicine, which inhibits XPO1. And
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot